Details:
Under the terms of the agreement, Lilly will continue the clinical development program beyond Phase 1 of CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor (AT2R) for the treatment of neuropathic pain.
Lead Product(s): CFTX-1554
Therapeutic Area: Neurology Product Name: CFTX-1554
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $630.0 million Upfront Cash: $40.0 million
Deal Type: Licensing Agreement March 02, 2023
Details:
CFTX-1554 is a novel inhibitor of AT2R, a clinically precedented target for the treatment of neuropathic pain. CFTX-1554 interacts more efficiently with the AT2R binding site, resulting in improved properties.
Lead Product(s): CFTX-1554
Therapeutic Area: Neurology Product Name: CFTX-1554
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2022
Details:
The grant will enable to further extend its current universal ConfoBody®, Cb35, toward other G proteins. The funds will also be used to identify additional universal ConfoBodies® for use in ConfoSensor® screening technology and lead neuropathic pain program, CFTX-1554.
Lead Product(s): CFTX-1554
Therapeutic Area: Neurology Product Name: CFTX-1554
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Flanders Innovation & Entrepreneurship
Deal Size: $1.8 million Upfront Cash: Undisclosed
Deal Type: Financing June 28, 2022
Details:
CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor (AT2R), is being developed as a non-opioid approach to the treatment of neuropathic pain, while avoiding centrally mediated side effects, such as addiction and sedation.
Lead Product(s): CFTX-1554
Therapeutic Area: Neurology Product Name: CFTX-1554
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2022
Details:
AbbVie has beefed up its neuro pipeline by acquiring Belgium-based Syndesi Therapeutics. This acquisition gives AbbVie access to Syndesi’s lead candidate SDI-118, a small molecule that is under evaluation to treat Alzheimer’s disease and major depressive disorder.
Lead Product(s): SDI-118
Therapeutic Area: Neurology Product Name: SDI-118
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $1,000.0 million Upfront Cash: $130.0 million
Deal Type: Acquisition March 01, 2022
Details:
RES19-T has shown to produce an acute response, restoring calcium homeostasis and synaptic plasticity, aim to address the disease at its root and restore cognition in patients by reducing the cellular damage associated with memory loss.
Lead Product(s): RES19-T
Therapeutic Area: Neurology Product Name: RES19-T
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2021
Details:
NVD-001 is Novadip’s first generation autologous cell-based osteogenic (bone healing) product derived from the Company’s proprietary tissue regeneration platform. Study met its primary endpoint. NVD-001 showed a favorable safety profile over a two-year observation period.
Lead Product(s): NVD-001
Therapeutic Area: Neurology Product Name: NVD-001
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2021
Details:
Proceeds from the fundraise will allow completion of proof-of-concept clinical trials for both the Alzheimer’s and the diabetes programs. A first-in-human trial of RES19-T for Alzheimer’s was initiated in 2020.
Lead Product(s): RES19-T
Therapeutic Area: Neurology Product Name: RES19-T
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Korys Investments
Deal Size: $29.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 21, 2021
Details:
RES19-T, a first-in-class small molecule, represents a novel approach to treat Alzheimer’s Disease (AD), aiming to address the disease at its root and restore cognition in patients by reducing the cellular damage associated with memory loss.
Lead Product(s): RES19-T
Therapeutic Area: Neurology Product Name: RES19-T
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020